193357-75-4

Usage

Uses

Used in Medicinal Chemistry:
4-(3,4-DIFLUORO-BENZYL)-PIPERIDINE HYDROCHLORIDE is used as a ligand for certain receptors or enzymes due to its potential to interact with biological targets, contributing to the development of new drugs.
Used in Drug Synthesis:
4-(3,4-DIFLUORO-BENZYL)-PIPERIDINE HYDROCHLORIDE is used as a building block in the synthesis of biologically active compounds, leveraging its chemical structure to create novel pharmaceutical agents.
Used in Pharmaceutical Formulations:
4-(3,4-DIFLUORO-BENZYL)-PIPERIDINE HYDROCHLORIDE is used as a potential anesthetic agent in pharmaceutical formulations, given its possible anesthetic properties, which could be beneficial in medical and surgical applications.
Used in Drug Development Industry:
4-(3,4-DIFLUORO-BENZYL)-PIPERIDINE HYDROCHLORIDE is used as a research compound for exploring its potential in drug development, where it may contribute to the discovery of new therapeutic agents and treatment options.

InChI:InChI=1/C12H15F2N.ClH/c13-11-2-1-10(8-12(11)14)7-9-3-5-15-6-4-9;/h1-2,8-9,15H,3-7H2;1H

Upstream product

• 1026501-51-8 1-benzyl-4-(3,4-difluoro-benzylidene)-piperidine 
• 85118-01-0 alpha-bromo-3,4-difluorotoluene 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Relevant academic research and scientific papers

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.